Thyroid Cancer Trial Results
Low-Dose Radioactive Iodine Destroys Thyroid Tissue Left after Surgery
(Posted: 06/07/2012) - A low dose of radioactive iodine given after surgery for thyroid cancer destroyed (ablated) residual thyroid tissue as effectively as a higher dose, with fewer side effects and less exposure to radiation, according to two European randomized controlled trials published May 3, 2012 in the New England Journal of Medicine.
Targeted Therapy Shows Benefit in Rare Type of Thyroid Cancer
(Posted: 12/02/2011) - Treatment with the multitargeted agent vandetanib (Caprelsa) improved progression-free survival in patients with medullary thyroid cancer (MTC), according to findings from a randomized clinical trial.
(Posted: 06/07/2012) - A low dose of radioactive iodine given after surgery for thyroid cancer destroyed (ablated) residual thyroid tissue as effectively as a higher dose, with fewer side effects and less exposure to radiation, according to two European randomized controlled trials published May 3, 2012 in the New England Journal of Medicine.
Targeted Therapy Shows Benefit in Rare Type of Thyroid Cancer
(Posted: 12/02/2011) - Treatment with the multitargeted agent vandetanib (Caprelsa) improved progression-free survival in patients with medullary thyroid cancer (MTC), according to findings from a randomized clinical trial.
